Drug intelligence / Profile preview

MSB-CAR001 + hyaluronan

Development stage: Phase 2
Lead developer: Mesoblast
Modality: Cell Therapies, Hydrogel Systems → Drug Delivery Systems
Administration: Intraarticular

Overview

MSB-CAR001 + hyaluronan is an investigational combination therapy evaluated for intra-articular injection following anterior cruciate ligament (ACL) reconstruction. The therapy consists of two components: MSB-CAR001, which is a preparation of mesenchymal precursor cells (MPCs), and hyaluronan, a naturally occurring glycosaminoglycan used as a viscosupplement to restore synovial fluid properties in the joint. The combination aims to enhance joint healing and recovery by leveraging the regenerative potential of MPCs together with the lubricating and shock-absorbing properties of hyaluronan. Clinical studies have focused on assessing safety and preliminary efficacy in patients post-ACL reconstruction[1][2][3][6].

Other names: hyaluronanhyaluronic acid

Beyond the preview

Go deeper on MSB-CAR001 + hyaluronan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSB-CAR001 + hyaluronan.